Ceralasertib
Tier C — Watch / tradeCeralasertib
Targets：ATR
Indications (approved)：Non-small cell lung cancer, Small cell lung cancer, 三阴性乳腺癌, Melanoma, Solid tumour, Osteosarcoma, Breast cancer, Metastatic breast cancer
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| AZD-6738-001 | 6299-85-0 | methyl 2,6-dichloropyrimidine-4-carboxylate |
| AZD-6738-002 | 74572-04-6 | (R)-3-methylmorpholine |
| AZD-6738-003 | 1233339-69-9 | methyl (R)-2-chloro-6-(3-methylmorpholino)pyrimidine-4-carboxylate |
| AZD-6738-004 | 1233339-70-2 | (R)-(2-chloro-6-(3-methylmorpholino)pyrimidin-4-yl)methanol |
| AZD-6738-005 | 1233339-71-3 | (R)-(2-chloro-6-(3-methylmorpholino)pyrimidin-4-yl)methyl methanesulfonate |
| AZD-6738-006 | 1233339-72-4 | (R)-4-(2-chloro-6-(iodomethyl)pyrimidin-4-yl)-3-methylmorpholine |
| AZD-6738-007 | 1352227-15-6 | (R)-4-(2-chloro-6-((methylthio)methyl)pyrimidin-4-yl)-3-methylmorpholine |
| AZD-6738-008 | 1352227-16-7 | (R)-4-(2-chloro-6-(((S)-methylsulfinyl)methyl)pyrimidin-4-yl)-3-methylmorpholine |
| AZD-6738-009 | 1352227-16-7 | (R)-4-(2-chloro-6-(((S)-methylsulfinyl)methyl)pyrimidin-4-yl)-3-methylmorpholine |
| AZD-6738-010 | 1352227-19-0 | N-(((2-chloro-6-((R)-3-methylmorpholino)pyrimidin-4-yl)methyl)(methyl)(oxo)-l6-sulfaneylidene)-2,2,2-trifluoroacetamide |
| AZD-6738-011 | 1352282-87-1 | (1-(2-chloro-6-((R)-3-methylmorpholino)pyrimidin-4-yl)cyclopropyl)(imino)(methyl)-l6-sulfanone |
| AZD-6738-012 | 850892-97-6 | tert-butyl 4-bromo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate |
| AZD-6738-013 | - | tert-butyl 4-(4-((R)-3-methylmorpholino)-6-(1-(S-methylsulfonimidoyl)cyclopropyl)pyrimidin-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate |
Frequently asked questions
What are the approved indications of Ceralasertib?
Approved indications include: Non-small cell lung cancer, Small cell lung cancer, 三阴性乳腺癌, Melanoma, Solid tumour, Osteosarcoma, Breast cancer, Metastatic breast cancer.
When does the Ceralasertib patent expire?
No public expiry year is available for Ceralasertib yet; this page updates once verified.
How many synthesis routes are recorded for Ceralasertib?
1 synthesis routes are recorded; the shortest is 12 steps with 0.086 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Ceralasertib intermediates?
All intermediates in Ceralasertib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Ceralasertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05